跳至主要内容
临床试验/NL-OMON31641
NL-OMON31641撤回不适用

The use of Progentix TCP (beta-tricalciumphosphate) as a bone substitute in defects originated from curettage of benign bone tumors - Progentix TCP as bone substitute after curettage of benign bone tumors

Medisch Spectrum Twente0 个研究点目标入组 10 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
撤回
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • benign bonetumors to be treated with curettage

排除标准

  • Use of Progentix TCP synthetic cancellous bone void filler is CONTRAINDICATED in the presence of one or more of the following clinical situations: Malignant bonetumors, In case of severe metabolic or systemic bone disorders that affect bone or wound healing, In case of acute and chronic infections in the operated area (soft tissue infections; inflamed, bacterial bone diseases; osteomyelitis), In case of treatment with pharmaceuticals interfering with the calcium metabolism.

研究者

相似试验